美国生物制药公司Harmony Biosciences Holdings, Inc.（简称Harmony Biosciences）近日宣布，其研发的Wakix®（Pitolisant）已获得美国食品药品监督管理局（FDA）的批准，新增用于治疗儿科患者发作性睡病中的猝倒症。这一重要监管决定标志着该药物在儿童患者群体中的应用获得扩展，为患有此罕见睡眠障碍的年轻患者提供了新的治疗选择。
美国生物制药公司Harmony Biosciences Holdings, Inc.（简称Harmony Biosciences）近日宣布，其研发的Wakix®（Pitolisant）已获得美国食品药品监督管理局（FDA）的批准，新增用于治疗儿科患者发作性睡病中的猝倒症。这一重要监管决定标志着该药物在儿童患者群体中的应用获得扩展，为患有此罕见睡眠障碍的年轻患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.